Steven Ferrucci, OD, FAAO
Dr. Ferrucci is Chief of optometry at the Sepulveda VA, as well as a professor at the Southern California College of Optometry. He currently serves on the advisory board for Maculogix.
Using OCTA in optometric practice
Using OCTA in optometric practice
By using OCTA technology, we are able to take better care of our patients with retinal disease, make smarter referrals, or be able to hold on to our patients, knowing a referral is not needed.
Retinal prosthesis offers hope to blind patients
An artificial retinal prosthesis allows patient with retinitis pigmentosa (RP) to locate objects, detect movement, and improve orientation and mobility skills.
A VA residency offers more than meets the eye
It’s 8:15 a.m. on Monday, and we are getting ready for another day of typical patient care while gulping down the last sips of our morning coffee. The first 8:30 a.m. patient arrives, and one of us heads out to greet him in the lobby.
Current views on genetic testing for AMD
Genetic testing in AMD is a relatively new focus for optometrists and an important one to ensure that we are getting a complete view of our patients’ risk for developing advanced AMD. Although we are making some progress, we still have work to do to gain a better understanding of how to incorporate its use into clinical practice.
MS medication may be associated with macula edema
Gilenya (Fingolimod, Novartis), a sphingosine-1-phosphate receptor modulator, became the first FDA-approved oral agent for the treatment of relapsing forms of multiple sclerosis (MS) in September 2010.1 Recently, it has been associated with macular edema, referred to as FAME, or Fingolimod-associated macular edema.
New technology may lead to earlier AMD Diagnosis
While there have been advances in the treatment of AMD, the methods to detect and diagnose AMD have remained the same, with the exception of OCT. But new technology—including the Adapt Dx, multi-spectral imaging, and fundus autofluorescence—may allow for earlier detection.
var script= ' ';